USPTO serial 79297241
SAGASIGN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 18, 2021
- Examiner
- HENRY, NAKIA D
- Law office
- TMO LAW OFFICE 129 - EXAMINING ATTORNEY ASSIGNED
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with SAGASIGN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $975
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sarah J. Schneider
Sarah J. Schneider Sheridan Ross P.C.1560 Broadway, Suite 1200Denver, CO 80202UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Nucleic acid sequences for medical and veterinary purposes; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing; diagnostic preparations and materials, namely, medical diagnostic reagents; chemical preparations for testing blood for medical purposes; chemical preparations for use in DNA analysis for medical purposes; chemical reagents for medical or veterinary purposes; chemical reagents for medical use; chemical reagents for veterinary use; chemical test reagents for medical purposes; chemical test reagents for veterinary purposes; clinical medical reagents; diagnostic agents for medical use; diagnostic biomarker reagents for medical purposes; diagnostic chemical reagents for medical use; diagnostic preparations for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic reagents for medical use; diagnostic testing materials for medical use; genetic identity tests comprised of reagents for medical purposes; in vitro diagnostic preparations for medical use; medical diagnostic reagents and assays for testing of body fluids; medical diagnostic test strips for analysis of blood and other liquids; preparations for detecting genetic predispositions for medical purposes; preparations for detecting mutation in prion genes for medical purposes; reactants for medical diagnosis being diagnostic reagents for medical purposes; reagents and media for medical and veterinary diagnostic purposes; reagents for analytical purposes for medical purposes; reagents for analytical purposes for veterinary purposes; reagents for blood grouping for medical purposes; reagents for in-vitro laboratory use for medical purposes; reagents for in-vitro laboratory use for veterinary purposes; reagents for microbiological analysis for medical purposes; reagents for microbiological analysis for veterinary purposes; reagents for use in analysis for medical purposes; reagents for use in analysis for veterinary purposes; reagents for use in diagnostic tests for medical purposes; reagents for use in diagnostic tests for veterinary purposes; reagents for use with analyzers for medical purposes; reagents for use with analyzers for veterinary purposes; reagents for use in diagnostic pregnancy tests; veterinary diagnostic reagents | ACTIVE | — |
| 042 | Analysis of human serum for medical research; analysis of human tissues for medical research; biological research, clinical research in the field of cancer and infectious diseases and medical research; clinical research in the field of cancer and infectious diseases; clinical trials for others; conducting early evaluations in the field of new pharmaceuticals; consultancy relating to laboratory testing; consultancy relating to pharmaceutical research and development; medical laboratory services; medical research; medical research laboratory services; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research and development; providing information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific information in the field of medical disorders and their treatment; provision of information and data relating to medical and veterinary pharmaceutical and diagnostic research and development; research and development for the pharmaceutical industry; research and development in the pharmaceutical and biotechnology fields; scientific research and development; scientific research for medical purposes in the area of cancerous diseases; services for assessing the efficiency of pharmaceuticals; services for assessing the efficiency of veterinary drugs | ACTIVE | — |
| 044 | Genetic counseling; genetic testing of animals for diagnostic or treatment purposes; laboratory analysis being medical analysis for diagnostic and treatment of persons provided by medical laboratories; medical and healthcare services; medical monitoring of patients; stem cell therapy services; medical services; analysis of human serum for medical treatment; analysis of human tissues for medical treatment; blood bank services; bowel cancer screening services; breast cancer screening services; cervical cancer screening services; colonoscopy screening services; medical consultancy and information services relating to medical products; DNA screening for medical purposes; genetic testing for medical purposes; hepatitis screening services; lung cancer screening services; medical advice in the field of pregnancy; medical analysis for the diagnosis and treatment of persons relating to cancer and infectious diseases; medical analysis services for the diagnosis of cancer; medical analysis services for cancer diagnosis and prognosis; medical analysis services for the diagnosis of cancer; medical analysis services relating to the treatment of patients relating to cancer and infectious diseases; medical analysis services relating to the treatment of persons for cancer and infectious diseases provided by a medical laboratory; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical and health services relating to DNA, genetics and genetic testing; medical care and analysis of cancer diagnosis relating to patient treatment; medical consultations; medical diagnostic services; medical evaluation services; medical analysis services for diagnostic and treatment purposes of blood samples taken from patients provided by medical laboratories; medical screening; medical services for the treatment of skin cancer; medical services in the field of oncology; medical testing for diagnostic or treatment purposes; medical testing services relating to the diagnosis and treatment of disease; prostate cancer screening services; providing cancer screening services; providing information in the field of medicine; RNA or DNA analysis for cancer diagnosis and prognosis; services for the testing of blood; services for the testing of sera; services for the testing of urine; services for the preparation of medical reports relating to health care; technical consultancy services relating to medical health; testicular cancer screening services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SAGA Diagnostics AB
- Other trademarks owned by SAGA Diagnostics AB
- Other trademarks owned by SAGA Diagnostics AB
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named SAGASIGN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 18, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jul 24, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 15, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 15, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 15, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Dec 15, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 15, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 15, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 21, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 25, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 3, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 3, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 18, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 18, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 15, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 2, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 2, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 24, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 24, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 10, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 22, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 31, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 30, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 30, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 20, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 3, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 3, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 19, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 19, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 19, 2020 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 19, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 19, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 19, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 17, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 16, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 13, 2020 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 10, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 6, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 6, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 5, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |